MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2025-09-30, JSPRW had $11,389K increase in cash & cash equivalents over the period.

Cash Flow Overview

Change in Cash
$11,389K

Unit: Thousand (K) dollars (except for numbers of shares and EPS)
Cash Flow
2025-09-30
2025-06-30
Total operating expense
19,166 -
Other income, net
430 -
Loss on disposal of property and equipment
--2
Net loss
-18,736 -47,964
Depreciation and amortization expense
229 537
Non-cash lease expense
326 508
Stock-based compensation expense
1,424 3,628
Change in fair value of warrant liability
-2,099 -
Offering costs recognized in other expense, net
2,046 -
Prepaid expenses and other current assets
209 -718
Other non-current assets
-42 -628
Accounts payable
1,132 4,007
Accrued expenses and other current liabilities
-700 391
Operating lease liability
-452 -750
Net cash used in operating activities
-16,999 -38,295
Purchases of property and equipment
0 7
Proceeds from sales of property and equipment
0 12
Proceeds from exercise of common stock options
-0
Net cash provided by (used in) investing activities
0 5
Proceeds from issuance of common stock through atm offering, net
514 5,940
Proceeds from issuance of common stock and warrants through underwritten offering, net
27,874 -
Proceeds from issuance of common stock pursuant to employee stock purchase plan
0 223
Net cash provided by financing activities
28,388 6,163
Net (decrease) increase in cash, cash equivalents and restricted cash
11,389 -32,127
Cash and cash equivalents at beginning of period
72,054 -
Cash and cash equivalents at end of period
51,316 -
Unit: Thousand (K) dollars

Time Plot

Show the time plot by selecting a row from the table.

Jasper Therapeutics, Inc. (JSPRW)

Jasper Therapeutics, Inc. (JSPRW)